<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759261</url>
  </required_header>
  <id_info>
    <org_study_id>2020/55</org_study_id>
    <secondary_id>SMAD4</secondary_id>
    <nct_id>NCT04759261</nct_id>
  </id_info>
  <brief_title>SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers; SMAD4 Protein Positivity</brief_title>
  <official_title>SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers; SMAD4 Protein Positivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trakya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trakya University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-melanocytic skin cancers are the most common type of cancer worldwide. In the development&#xD;
      of this cancer type, environmental factors such as UV and smoking are emphasized.&#xD;
&#xD;
      Epigenetics are genetic conditions that develop due to environmental factors and can be&#xD;
      inherited. Epigenetic modifications such as DNA methylation play an integral role in&#xD;
      carcinogenesis, cancer progression and metastasis.&#xD;
&#xD;
      The TGF-/ SMAD4 pathway plays a tumor suppressive role in cancer pathogenesis. Epigenetic&#xD;
      changes in this pathway also lead to a decrease in expression level, leading to different&#xD;
      types of cancer. However, there is no study showing the epigenetic relationship between&#xD;
      non-melanocytic skin cancer and SMAD4 methylation.&#xD;
&#xD;
      In this study we planned, it was aimed to show the change in SMAD4 methylation and SMAD4 RNA&#xD;
      expression level in cancerous tissue. In addition, it is planned to measure the SMAD4 protein&#xD;
      positivity rate in non-melanocytic cancers as an immunohistochemical marker.&#xD;
&#xD;
      In this context, 60 patients who applied to Trakya University Dermatology and Venereal&#xD;
      Diseases Outpatient Clinic and diagnosed with non-melanocytic skin cancer clinically and&#xD;
      dermoscopically will be included in the study. Tissue materials obtained from both cancerous&#xD;
      and intact skin of the patients will be examined in Trakya University Medical Biophysics and&#xD;
      Medicine Pathology laboratories through various steps.&#xD;
&#xD;
      Our project is the first study to be conducted on this subject in terms of handling all&#xD;
      non-melanocytic skin cancers, using human tissue and having a large sample.&#xD;
&#xD;
      In addition, with the data to be obtained; We think that better clarification of the role of&#xD;
      SMAD4 in non-melanocytic cancers and the use of SMAD4 as both a prognostic factor and an&#xD;
      immunohistochemical marker in future studies will prevent this study.&#xD;
&#xD;
      Again, we anticipate that different treatment modalities will be developed and different&#xD;
      functional studies can be designed through this pathway.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Differantiation of tumor tissues than normal tissues in same patients.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of SMAD4 methylations and expression</measure>
    <time_frame>2 years</time_frame>
    <description>Detection of SMAD4 methylations on tumor tissues</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SMAD4 expression and methylation</intervention_name>
    <description>Effect of SMAD4 methylations on smad4 expression</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. People diagnosed clinically and dermoscopically with non-melanocytic skin cancer&#xD;
&#xD;
          2. No other cancer history&#xD;
&#xD;
          3. over 18 years old&#xD;
&#xD;
          4. Newly diagnosed&#xD;
&#xD;
          5. No systemic or topical therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under 18 and pregnant&#xD;
&#xD;
          2. People with non-melanocytic skin cancer who are in the process of follow-up and&#xD;
             treatment&#xD;
&#xD;
          3. has another cancer history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Metin Budak</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trakya University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatma El Usturali Keskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trakya University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yildiz Gursel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trakya University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yildiz Gursel, MD</last_name>
    <phone>90 505 537 30 63</phone>
    <email>yildizgrsl@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Trakya University</name>
      <address>
        <city>Edirne</city>
        <zip>22000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yildiz Gursel, MD</last_name>
      <phone>+905055373063</phone>
      <email>ygurselu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Metin Budak, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatma El Ustrali Keskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Trakya University</investigator_affiliation>
    <investigator_full_name>Metin Budak</investigator_full_name>
    <investigator_title>Asist. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Basal Cell Carcinoma</keyword>
  <keyword>Squamose Cell Carcinoma</keyword>
  <keyword>Actinic Keratoses</keyword>
  <keyword>SMAD4 methylation</keyword>
  <keyword>SMAD4 expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

